This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?
This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.
This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.
The AURORA-1 trial. Sparkling with hope for lupus nephritis. Will this make it easier for rheumatologists to prescribe a CNI? Can you overcome the sticker shock to examine the benefits and weaknesses of AURORA-1. Let’s dive in.